Form 8-K NEUROCRINE BIOSCIENCES For: Dec 22
- Wall Street rallies as Fed minutes meet expectations
- NVIDIA Shares Drop 6% on Disappointing Guidance, While Q1 Earnings Beat
- Apple (AAPL) Reportedly Behind Schedule in Development of the New iPhone, Analyst Cuts Price Target on Risk to June Quarter iPhone Revenue
- Oil edges higher on tight supply, rising U.S. refining activity
- After-Hours Stock Movers 05/25: NVIDIA, Snowflake Sink on Weaker Guidance; Williams-Sonoma Surges on Strong Numbers (more...)
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 22, 2021
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
(Address of Principal Executive Offices)
Registrant’s Telephone Number, Including Area Code: (
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
On November 22, 2021, Neurocrine Biosciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “License Agreement”) with Heptares Therapeutics Limited (“Heptares”), which provides that the License Agreement becomes effective upon the expiration or termination of applicable waiting periods and the receipt of any required approvals or clearances under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), as previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 22, 2021. The expiration of the applicable waiting periods under the HSR Act was on December 22, 2021, and the License Agreement became effective on December 22, 2021 (the “Effective Date”). Under the terms of the License Agreement, the Company has agreed to pay Heptares an upfront payment of $100.0 million within ten days of the Effective Date.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|NEUROCRINE BIOSCIENCES, INC.|
|Dated: December 23, 2021||/s/ Darin M. Lippoldt|
|Darin M. Lippoldt|
|Chief Legal Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Neurocrine Biosciences (NBIX) Presents INGREZZA Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms
- HawkEye 360 Launches Next-Generation Cluster 5 Satellites
- The Estée Lauder Companies to Present at Bernstein’s 38th Annual Strategic Decisions Conference
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!